Takeda maintains commitment to drug pricing plan as Trump demands lower prices & more — 3 GI companies making waves

The following GI/endoscopy companies made headlines this week.

Here are three to note:

Parsippany-Troy Hills, N.J.-based Allergan elected Adriane Brown to its board of directors. Ms. Brown is the current president and COO of Bellevue, Wash.-based Intellectual Ventures.  

Ahead of its stock offering, the FDA approved New York City-based Synergy Pharmaceuticals' plecanatide. The drug treats chronic idiopathic constipation in adults.

After President Donald Trump demanded pharmaceutical companies offer cheaper drugs, Japan-based Takeda renewed its commitment to its single-digit annual increase pricing model. President Trump would like pharmaceutical companies to lower prices and produce more drugs in the United States.

Takeda's Chief Executive Christophe Weber said in a results briefing that "Takeda has for many years been reasonable in its price increases in the United States and we are very committed to single-digit price increase [model]."

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

ASC_GI_300x250

Featured Webinars

Featured Whitepapers

Featured Podcast